Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.

Clinical pharmacology and therapeutics - 1 Dec 2008

Franke R M, Baker S D, Mathijssen R H, Schuetz E G, Sparreboom A

Abstract excerpt

We hypothesized that the assessment of baseline CYP3A4 activity is influenced by probe-specific differences in hepatocellular uptake mechanisms. There was no significant correlation between the erythromycin breath test (ERMBT) parameters and midazolam clearance in 30 cancer patients (R(2) < 0.01)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breath Tests
Share to Drug Administration Schedule
Share to Erythromycin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatocytes

Share to Midazolam

Share to Molecular Probe Techniques

Share to Organic Anion Transporters, Sodium-Independent

Share to Solute Carrier Organic Anion Transporter Family Member 1B3

Source

Identifiers

PMID: 18509328
DOI: 10.1038/clpt.2008.94

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-18509328-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.PMID 18509328Read ↗

Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin.Semantic proximity Read ↗

Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.Semantic proximity Read ↗

The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literatureSemantic proximity Read ↗

CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.Semantic proximity Read ↗

Factors affecting cytochrome P-450 3A activity in cancer patients.Semantic proximity Read ↗

IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAYSemantic proximity Read ↗

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.Semantic proximity Read ↗

Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.Semantic proximity Read ↗

Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.Semantic proximity Read ↗

Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.Semantic proximity Read ↗

Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers.Semantic proximity Read ↗

Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.